News

4 stock recommendations by global brokerages

BofA on Aurobindo PharmaShutterstock.com
1/5
BofA on Aurobindo Pharma
BofA Securities maintains 'buy' rating on Aurobindo Pharma with a target price of Rs 634 per share. Unit-4 VAI status gives a sigh of relief for the company, it said, adding that the US FDA compliance score improves with this development.
JP Morgan on Ashok LeylandShutterstock.com
2/5
JP Morgan on Ashok Leyland
JP Morgan maintains 'neutral' rating on Ashok Leyland with a target price of Rs 75 per share. The company's Q3 disappointed on margin miss. The volume growth recovery remains elusive, the brokerage said. The scrappage policy is a key monitorable, it added.
Macquarie on Bandhan BankPTI
3/5
Macquarie on Bandhan Bank
Macquarie maintains 'underperform' rating on Bandhan Bank with a target price of Rs 470 per share. Macquarie believes that too much is going on both fundamental level & stake-sale level in the bank and therefore, this is not the right time to buy the stock given the uncertainties.
JP Morgan on Indian HotelsShutterstock.com
4/5
JP Morgan on Indian Hotels
JP Morgan maintains 'overweight' rating on Indian Hotels with a target price of Rs 175 per share. The brokerage said Q3 sees RevPAR recovery across the industry. Mumbai, Delhi, Bangalore and Hyderabad all showed good results.
CLSA on FinancialsShutterstock.com
5/5
CLSA on Financials
Banks’ credit quality wait gets longer, CLSA said. The recoveries from NCLT aided Q3 earnings. PSU banks’ performance highlights the consolidation phase as banks prepare for life post-mergers.
Text Size:AAA
Markets Data

*

Success
This article has been saved